Casdin Capital 13F holdings, Q4 2022
Holdings as of December 31, 2022 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 44 US equity positions worth $1.3bn in its Q4 2022 13F filing. The largest position was SRPT at 13.3% of the reported book, followed by BLFS and EQRX INC. Against the Q3 2022 filing, it opened 11 new positions, added to 10 and reduced 7 among the top 44 holdings.
What did Casdin Capital own in Q4 2022? Top 44 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2022 |
|---|---|---|---|---|---|---|---|
| 1 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 13.3% | $170.4m | 1,315,000 | 7% | added |
| 2 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 10.8% | $137.7m | 7,566,292 | 0% | held |
| 3 | EQRX INC | 7.6% | $97.2m | 39,527,669 | 0% | held | |
| 4 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 6.8% | $86.7m | 365,000 | -44% | reduced |
| 5 | ILMN ILLUMINA INC | Healthcare | 6.1% | $77.8m | 385,000 | 0% | held |
| 6 | 2655787D BLUEPRINT MEDICINES CORP | 5.1% | $64.7m | 1,477,800 | -13% | reduced | |
| 7 | RVMD REVOLUTION MEDICINES INC | Healthcare | 4.7% | $60.1m | 2,525,000 | 0% | held |
| 8 | MXCT MAXCYTE INC | 4.1% | $51.9m | 9,505,000 | -11% | reduced | |
| 9 | RLAY RELAY THERAPEUTICS INC | Healthcare | 3.5% | $45.3m | 3,030,648 | -35% | reduced |
| 10 | VERVE THERAPEUTICS INC | 3.5% | $44.3m | 2,290,571 | -28% | reduced | |
| 11 | DNLI DENALI THERAPEUTICS INC | Healthcare | 2.8% | $36.2m | 1,300,000 | 31% | added |
| 12 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 2.5% | $32.4m | 1,675,000 | 123% | added |
| 13 | SOMALOGIC INC | 2.5% | $31.6m | 12,604,275 | 0% | held | |
| 14 | EXK EXACT SCIENCES CORP | Basic Materials | 2.2% | $28.0m | 565,000 | -42% | reduced |
| 15 | ABCL ABCELLERA BIOLOGICS INC | Healthcare | 1.8% | $23.0m | 2,270,000 | 38% | added |
| 16 | TWST TWIST BIOSCIENCE CORP | Healthcare | 1.8% | $22.5m | 945,000 | 159% | added |
| 17 | MIRATI THERAPEUTICS INC | 1.7% | $21.5m | 475,000 | 90% | added | |
| 18 | FATE FATE THERAPEUTICS INC | Healthcare | 1.6% | $20.7m | 2,050,000 | 0% | held |
| 19 | AVIDITY BIOSCIENCES INC | 1.5% | $18.9m | 850,000 | – | new | |
| 20 | 2SEVENTY BIO INC | 1.4% | $17.3m | 1,850,000 | 201% | added | |
| 21 | INVITAE CORP | 1.3% | $16.8m | 9,038,388 | 703% | added | |
| 22 | PROMETHEUS BIOSCIENCES INC | 1.3% | $16.5m | 150,000 | – | new | |
| 23 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 1.3% | $16.4m | 3,206,380 | 0% | held |
| 24 | ABSI ABSCI CORPORATION | 1.2% | $15.5m | 7,363,260 | -5% | reduced | |
| 25 | BEAM BEAM THERAPEUTICS INC | Healthcare | 1.1% | $14.5m | 370,000 | 0% | held |
| 26 | 4D MOLECULAR THERAPEUTICS IN | 1.1% | $14.0m | 630,000 | – | new | |
| 27 | PRME PRIME MEDICINE INC | 1.1% | $13.6m | 734,350 | – | new | |
| 28 | TNYA TENAYA THERAPEUTICS INC | 1.0% | $12.2m | 6,078,860 | 69% | added | |
| 29 | MRNA MODERNA INC | Healthcare | 0.8% | $10.8m | 60,000 | 85% | added |
| 30 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 0.8% | $10.3m | 295,000 | 0% | held |
| 31 | VEEV VEEVA SYS INC | Healthcare | 0.6% | $8.1m | 50,000 | – | new |
| 32 | ARVN ARVINAS INC | Healthcare | 0.5% | $6.8m | 200,000 | 0% | held |
| 33 | INCY INCYTE CORP | Healthcare | 0.5% | $6.2m | 77,500 | – | new |
| 34 | DICE THERAPEUTICS INC | 0.4% | $5.1m | 165,000 | – | new | |
| 35 | OPRX OPTIMIZERX CORP | Healthcare | 0.3% | $4.4m | 260,000 | – | new |
| 36 | WGS SEMA4 HOLDINGS CORP | 0.3% | $4.3m | 16,437,500 | 0% | held | |
| 37 | DH DEFINITIVE HEALTHCARE CORP | Healthcare | 0.3% | $4.0m | 360,000 | – | new |
| 38 | GLUE MONTE ROSA THERAPEUTICS INC | 0.3% | $3.9m | 510,882 | 0% | held | |
| 39 | KROS KEROS THERAPEUTICS INC | Healthcare | 0.2% | $3.1m | 65,000 | – | new |
| 40 | SINGULAR GENOMICS SYSTEMS IN | 0.2% | $2.7m | 1,345,722 | 0% | held | |
| 41 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 0.1% | $1.4m | 200,000 | – | new |
| 42 | EXSCIENTIA PLC | 0.1% | $1.1m | 213,900 | 0% | held | |
| 43 | LIANY LIANBIO | 0.0% | $338.5k | 206,415 | 0% | held | |
| 44 | KRONOS BIO INC | 0.0% | $200.6k | 123,839 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.